Original-Research: K+S AG (von Parmantier & Cie. GmbH): Buy
^
Original-Research: K+S AG - from Parmantier & Cie. GmbH
18.11.2026 / 11:25 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS
Group.
The issuer is solely responsible for the content of this research. The
result of this research does not constitute investment advice or an
invitation to conclude certain stock exchange transactions.
---------------------------------------------------------------------------
Classification of Parmantier & Cie. GmbH to K+S AG
Company Name: K+S AG
ISIN: DE000KSAG888
Reason for the research: Valuation Upgrade to Buy
Recommendation: Buy
from: 18.11.2026
Target price: 17,50
Last rating change: Hold
Analyst: René Parmantier
PRESS RELEASE
K+S: Parmantier & Cie. Research upgrades to Buy - EUR17.50 target
Valuation upgrade after share-price decline; approximately 35% upside to
unchanged target
Frankfurt am Main, 18 November 2026. Parmantier & Cie. Research upgrades K+S
from Hold to Buy, retaining its EUR17.50 price target. Against the EUR12.97
reference price, the Xetra close on 16 November 2026, this implies
approximately 35% price upside and a 36% expected 12-month total return
including the PCR dividend estimate.
The valuation upgrade follows the share-price decline from around EUR17 to
EUR12-13. PCR sees a more attractive entry point into a cyclical recovery. The
spring season is the next test: PCR expects high capacity utilisation, while
Baltic logistics constraints may restrict effective supply. This is PCR's
assessment, not K+S guidance.
PCR forecasts EBITDA of approximately EUR709m for 2027 and EUR810m for 2028,
around 2% and 15% above Vara consensus dated 14 October 2026. K+S has not
yet issued formal 2027 guidance. PCR expects the clearest cash-flow relief
in 2029, following the completion of Werra 2060 planned for summer 2028.
The share purchase by CFO Dr. Jens Christian Keuthen and Rossmann's larger
disclosed position provide additional context. Rossmann reported a combined
position of 20.04%, comprising 7.98% in direct shares and 12.06% through
instruments. PCR views this as a positive confidence signal, not evidence of
intrinsic value.
Risks remain potash prices, farmer affordability, additional supply, project
execution, energy costs and cash conversion.
Request the full study and join our research mailing list:
For the full study and inclusion on the research mailing list, contact:
research@parmantiercie.com.
Parmantier & Cie. Research | René Parmantier
Independent, unsolicited and unpaid research. This release summarises the
study and does not replace its full risk and conflict-of-interest
disclosures or constitute personalised investment advice. Targets and
forecasts are not guarantees.
You can download the research here:
https://nwr.eqs-cockpit.com/fncls2.ssx?fn=redirect&u=4794bd785d5e4852f263b171a01013a3
Contact for questions:
---------------------------------------------------------------------------
The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
View original content:
https://eqs-news.com/?origin_id=36cedd21-e338-11f1-b46d-066675bb9927&lang=en
---------------------------------------------------------------------------
2437602 18.11.2026 CET/CEST
°